- Expectancy effects significantly predicted psychological improvements, including reductions in anxiety and depressive symptoms, as well as enhancements in psychological resilience and connectedness.
- Microdosing may serve as an active placebo, where the positive outcomes might be influenced by an individual’s expectations rather than solely the pharmacological effects of the substances.
- The study highlights the need for future research to include control groups and a blend of subjective and objective measures to better understand the impact of microdosing on mental health.
Introduction
This prospective survey study included 81 participants and investigated the effects of psychedelic microdosing on mental health outcomes. The key focus was on how positive expectations could shape the perceived benefits of microdosing, specifically concerning state anxiety and depressive symptoms over a four-week period.
Study Overview
The researchers designed the study to collect web-based data from individuals intending to microdose psychedelics, primarily psilocybin or LSD. Participants completed surveys before, during, and after a structured microdosing regimen, allowing the researchers to examine fluctuations in psychological well-being, emotional stability, and mental health symptoms. Their findings demonstrated marked increases in self-reported psychological health and reductions in anxiety and depressive symptoms at the four-week endpoint.
Expectancy Effects
The study underscored the significant role that participants’ expectations regarding the efficacy of microdosing had on their reported mental health improvements. Individuals who held positive anticipations experienced more substantial enhancements in well-being, which suggest a considerable placebo effect. In the context of microdosing, this implies that the perceived therapeutic benefits might be largely tied to these expectations rather than purely the therapeutic action of the substances.
Clinical Implications and Future Research
While the findings provide insights into the potential benefits of microdosing, the study faced limitations, including a lack of a placebo control group and the challenges of assessing long-term effects due to participant attrition after the study period. Furthermore, many participants reported prior experience with psychedelics, signaling a potential bias that might confound the results. Future studies should consider implementing appropriate active placebos to maintain study integrity while exploring the effects of microdosing in various settings, including clinical populations.
Conclusion
In conclusion, this study offers initial evidence of the importance of positive expectancies in predicting mental health outcomes associated with psychedelic microdosing. The researchers advocate for further exploration into the intricate relationship between expectations and pharmacological effects to enhance the understanding of microdosing’s role in mental health treatments.
Read the full paper summary on Blossom.
